Company intelligence / Profile preview

Minerva

Waltham, Massachusetts, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Minerva Biotechnologies has completed the first successful human trial of a CAR T cell therapy for solid tumors targeting MUC1* and received FDA approval for huMNC2-CAR44 T cells in metastatic breast cancer. ADC program expected to reach IND submission soon.

Therapeutic areas: Oncology
Modalities: Autologous CAR-TAntibody drug conjugate (ADC)Small moleculeCell therapyT-lymphocyte cell therapy
Industry: Biotech

Partnerships

Memorial Sloan Kettering Cancer CenterCellSystems

Beyond the preview

Go deeper on Minerva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minerva.

Explore the full profile